165 related articles for article (PubMed ID: 21877196)
1. Possible association of NAT2 polymorphism with laryngeal cancer risk: an evidence-based meta-analysis.
Ying XJ; Dong P; Shen B; Wang J; Wang S; Wang G
J Cancer Res Clin Oncol; 2011 Nov; 137(11):1661-7. PubMed ID: 21877196
[TBL] [Abstract][Full Text] [Related]
2. NAT2 polymorphism and gastric cancer susceptibility: a meta-analysis.
Zhong X; Hui C; Xiao-Ling W; Yan L; Na L
Arch Med Res; 2010 May; 41(4):275-80. PubMed ID: 20637371
[TBL] [Abstract][Full Text] [Related]
3. NAT2 polymorphisms combining with smoking associated with breast cancer susceptibility: a meta-analysis.
Zhang J; Qiu LX; Wang ZH; Wang JL; He SS; Hu XC
Breast Cancer Res Treat; 2010 Oct; 123(3):877-83. PubMed ID: 20180012
[TBL] [Abstract][Full Text] [Related]
4. A meta-analysis of the relationship between NAT2 polymorphism and colorectal cancer susceptibility.
Liu H; Fu ZX; Wang CY; Qian J; Xing L; Liu YW
Medicina (Kaunas); 2012; 48(3):117-31. PubMed ID: 22588343
[TBL] [Abstract][Full Text] [Related]
5. NAT2 slow acetylation genotypes contribute to asthma risk among Caucasians: evidence from 946 cases and 1,091 controls.
Wang Y; Zhang Q; Zhang M; Wang C
Mol Biol Rep; 2014 Mar; 41(3):1849-55. PubMed ID: 24442317
[TBL] [Abstract][Full Text] [Related]
6. N-acetyltransferase 2 phenotype and risk of esophageal cancer: a meta analysis.
Ma RL; Min L; Chen D; Tao WP; Ge W; Wu YG
Cancer Biomark; 2013 Jan; 13(6):447-55. PubMed ID: 24595082
[TBL] [Abstract][Full Text] [Related]
7. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
García-Closas M; Malats N; Silverman D; Dosemeci M; Kogevinas M; Hein DW; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Castaño-Vinyals G; Yeager M; Welch R; Chanock S; Chatterjee N; Wacholder S; Samanic C; Torà M; Fernández F; Real FX; Rothman N
Lancet; 2005 Aug 20-26; 366(9486):649-59. PubMed ID: 16112301
[TBL] [Abstract][Full Text] [Related]
8. Association Between N-acetyltransferase 2 Polymorphism and Bladder Cancer Risk: Results From Studies of the Past Decade and a Meta-Analysis.
Wu H; Wang X; Zhang L; Mo N; Lv Z
Clin Genitourin Cancer; 2016 Apr; 14(2):122-9. PubMed ID: 26585839
[TBL] [Abstract][Full Text] [Related]
9. N-acetyltransferase-2 gene polymorphism as a possible biomarker for prostate cancer in Japanese men.
Hamasaki T; Inatomi H; Katoh T; Aono H; Ikuyama T; Muratani T; Matsumoto T
Int J Urol; 2003 Mar; 10(3):167-73. PubMed ID: 12622714
[TBL] [Abstract][Full Text] [Related]
10. Lack of association between glutathione S-transferase T1 gene polymorphism and laryngeal cancer susceptibility: a meta-analysis based on 2,124 cases and 2,059 controls.
Ying XJ; Xu CZ; Xu HM; Sun ZF; Zhang J; Wang GL; Dong P
Gene; 2012 Feb; 494(1):11-6. PubMed ID: 22207034
[TBL] [Abstract][Full Text] [Related]
11. Glutathione S-transferase M1 gene polymorphism and laryngeal cancer risk: a meta-analysis.
Ying XJ; Dong P; Shen B; Xu CZ; Xu HM; Zhao SW
PLoS One; 2012; 7(8):e42826. PubMed ID: 22900055
[TBL] [Abstract][Full Text] [Related]
12. Association between N-acetyltransferase 2 (NAT2) genetic polymorphism and development of breast cancer in post-menopausal Chinese women in Taiwan, an area of great increase in breast cancer incidence.
Huang CS; Chern HD; Shen CY; Hsu SM; Chang KJ
Int J Cancer; 1999 Jul; 82(2):175-9. PubMed ID: 10389748
[TBL] [Abstract][Full Text] [Related]
13. NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis.
Suvichapanich S; Fukunaga K; Zahroh H; Mushiroda T; Mahasirimongkol S; Toyo-Oka L; Chaikledkaew U; Jittikoon J; Yuliwulandari R; Yanai H; Wattanapokayakit S; Tokunaga K
Pharmacogenet Genomics; 2018 Jul; 28(7):167-176. PubMed ID: 29781872
[TBL] [Abstract][Full Text] [Related]
14. N-acetyltransferase 2 acetylator genotype-dependent N-acetylation of 4-aminobiphenyl in cryopreserved human hepatocytes.
Habil MR; Doll MA; Hein DW
Pharmacogenet Genomics; 2020 Apr; 30(3):61-65. PubMed ID: 31895247
[TBL] [Abstract][Full Text] [Related]
15. N-acetyltransferase (NAT2) polymorphism and breast cancer susceptibility: a lack of association in a case-control study of Turkish population.
Kocabaş NA; Sardaş S; Cholerton S; Daly AK; Karakaya AE
Int J Toxicol; 2004; 23(1):25-31. PubMed ID: 15162844
[TBL] [Abstract][Full Text] [Related]
16. The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis.
Zhang M; Wang S; Wilffert B; Tong R; van Soolingen D; van den Hof S; Alffenaar JW
Br J Clin Pharmacol; 2018 Dec; 84(12):2747-2760. PubMed ID: 30047605
[TBL] [Abstract][Full Text] [Related]
17. [Relationship between polymorphism of N-acetyltransferase 2 and genetic susceptibility to laryngeal carcinoma].
Lei D; Pan X; Guo C; Xu F; Zhang L; Liu D; Luan X
Zhonghua Zhong Liu Za Zhi; 2002 Mar; 24(2):154-6. PubMed ID: 12015038
[TBL] [Abstract][Full Text] [Related]
18. The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis.
Yee J; Kim SM; Han JM; Lee N; Yoon HY; Gwak HS
Sci Rep; 2020 Feb; 10(1):3658. PubMed ID: 32107440
[TBL] [Abstract][Full Text] [Related]
19. Association between N-Acetyltransferase 2 Polymorphism and Bladder Cancer Risk: a Meta-Analysis in a Single Ethnic Group.
Xu WJ; Wen LP; Jiang XX; Ye LY; Meng FH; Guan S; Qian YJ; Wei JF
Clin Lab; 2017 Feb; 63(2):287-293. PubMed ID: 28182356
[TBL] [Abstract][Full Text] [Related]
20. Association between N-acetyltransferase 2 polymorphisms and pancreatic cancer risk: a meta-analysis.
Liang JX; Gao W; Liang Y; Zhou XM
Genet Mol Res; 2015 Dec; 14(4):17219-27. PubMed ID: 26681215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
